Amicus Therapeutics (FOLD) Fundamental Analysis: Revenue, Earnings & Valuation

2.11 / 10

Underperform

Fundamental rating is Underperform with a 2.11/10 score. Profit‑MV and Cash‑MV show modest strength, while Asset‑MV and Revenue‑MV are markedly negative. Margins and turnover ratios are mixed, leading to an overall concerning financial profile.

Analysis Checks(6/10)

Revenue-MV

Value-0.99

Score1/3

Weight36.70%

1M Return5.44%

Inventory turnover ratio

Value0.42

Score2/3

Weight-2.70%

1M Return-0.56%

Gross profit margin (%)

Value88.50

Score0/3

Weight-21.35%

1M Return-5.42%

Profit-MV

Value0.68

Score2/3

Weight41.90%

1M Return6.36%

Income tax / Total profit (%)

Value14293.72

Score2/3

Weight5.26%

1M Return0.98%

Current assets turnover ratio

Value1.07

Score1/3

Weight-0.91%

1M Return-0.17%

Fixed assets turnover ratio

Value22.45

Score2/3

Weight0.05%

1M Return0.01%

Cost of sales ratio (%)

Value11.50

Score2/3

Weight-17.17%

1M Return-3.62%

Asset-MV

Value-0.55

Score0/3

Weight17.19%

1M Return2.73%

Cash-MV

Value-1.96

Score2/3

Weight41.05%

1M Return6.19%

Is FOLD undervalued or overvalued?

FOLD scores 2.11/10 on fundamentals and holds a Premium valuation at present. Backed by its -11.58% ROE, -4.27% net margin, -166.90 P/E ratio, 16.50 P/B ratio, and 50.00% earnings growth, these metrics solidify its Underperform investment rating.